Clinical trial
Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2
NCT00906061 is registered in ClinicalTrials.gov with Hospital Arnau de Vilanova as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2
- Lead sponsor
- Hospital Arnau de Vilanova
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 31, 2007
- Completion date
- October 31, 2011
- Enrollment
- 76 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.